180 Life Sciences Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? (Deficit) Equity (Details)

Stockholders’ (Deficit) Equity (Details) - USD ($)							3 Months Ended		6 Months Ended
Stockholders’ (Deficit) Equity (Details) - USD ($)	May 13, 2024	Apr. 23, 2024	Mar. 31, 2024	Nov. 28, 2023	Sep. 07, 2023	Aug. 09, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Feb. 29, 2024	Feb. 16, 2024	Dec. 31, 2023	Aug. 31, 2023	Apr. 30, 2023	Dec. 31, 2022	Jul. 31, 2022
Stockholders’ (Deficit) Equity [Line Items]
Common stock shares (in Shares)							941,590		941,590				534,719
Aggregate shares of common stock (in Shares)						35,102
Pre-funded warrants (in Shares)				257,205
Common stock warrants to purchase (in Shares)				477,058
Purchase price per share (in Dollars per share)						$ 12.35
Net proceeds						$ 2,700,000
Additional paid in capital						$ 300,000	$ 130,899,278		$ 130,899,278				$ 130,117,209
Purchaser agreed to pay				$ 830,769
Warrants exercise price (in Dollars per share)				$ 3.23
Stock-based compensation expense							22,308	$ 551,310	258,370	$ 1,108,731
General and administrative expenses								80,607		167,325
Unrecognized stock-based compensation expense							232,740		$ 232,740
Recognized over the weighted average remaining vesting period									1 year 4 months 24 days
August 2023 Pre-Funded Warrants [Member]
Stockholders’ (Deficit) Equity [Line Items]
Pre-funded warrants (in Shares)						207,814
August 2023 Common Warrants [Member]
Stockholders’ (Deficit) Equity [Line Items]
Common stock warrants to purchase (in Shares)						242,915
Warrant [Member]
Stockholders’ (Deficit) Equity [Line Items]
Aggregate gross proceeds						$ 2,999,606
Maximum [Member]
Stockholders’ (Deficit) Equity [Line Items]
Shares issued under the plan (in Shares)									24,736
Minimum [Member]
Stockholders’ (Deficit) Equity [Line Items]
Shares issued under the plan (in Shares)									223,679
Common Stock [Member]
Stockholders’ (Deficit) Equity [Line Items]
Share price (in Dollars per share)												$ 0.0001
General and Administrative Expenses [Member]
Stockholders’ (Deficit) Equity [Line Items]
Stock-based compensation expense							20,358	$ 470,703	$ 234,113	$ 941,406
Research and Development Expense [Member]
Stockholders’ (Deficit) Equity [Line Items]
Stock-based compensation expense							$ 1,950		$ 3,900
Amendment to the August 2023 Offering [Member]
Stockholders’ (Deficit) Equity [Line Items]
Warrants exercise price (in Dollars per share)				$ 0.0019
Class K Special Voting Shares [Member]
Stockholders’ (Deficit) Equity [Line Items]
Number of shares (in Shares)									14
Former Board [Member]
Stockholders’ (Deficit) Equity [Line Items]
Common stock shares (in Shares)		63,818
Compensate accrued board of director fees		$ 112,024
Recognized loss		$ 9,230
Nasdaq Capital Market [Member]
Stockholders’ (Deficit) Equity [Line Items]
Stockholders’ equity					$ 2,500,000
Director [Member]
Stockholders’ (Deficit) Equity [Line Items]
Granted options for purchase of shares (in Shares)	2,500,000
Common Stock [Member] \| Class K Special Voting Shares [Member]
Stockholders’ (Deficit) Equity [Line Items]
Number of shares (in Shares)									14
Amendment to August 2023 Offering [Member]
Stockholders’ (Deficit) Equity [Line Items]
Common stock shares (in Shares)			257,205								257,205			242,915	82,668	135,339	16,138
Offering were exercised			$ 489
Amendment to August 2023 Offering [Member] \| Warrants to Purchase Common Stock [Member]
Stockholders’ (Deficit) Equity [Line Items]
Warrants exercise price (in Dollars per share)							$ 3.23		$ 3.23